Dr. Gadi on Preferences for Treating Relapsed HER2+ Metastatic Breast Cancer: OncLive

Dr. VK Gadi, leads a panel discussion of breast oncologists highlighting their therapy preferences for a woman with HER2-positive metastatic breast cancer previously treated with docetaxel-trastuzumab-pertuzumab followed by paclitaxel and cisplatin.

The University of Illinois Cancer Center serves as a Strategic Alliance Partner with OncLive.
View our complete video library.

Translate »